Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome
- Registration Number
- NCT00372125
- Lead Sponsor
- Karolinska University Hospital
- Brief Summary
The aim of this study is to study the effects of GH on body composition, lipid and glucose metabolism, physical performance and safety aspects in adults with PWS.The patients are randomized to either GH or placebo the first year of the study, subsequently followed by two years of GH treatment. the study is performed in Norway, Sweden and Denmark.
- Detailed Description
OBJECTIVE(S):
Prader Willi syndrome (PWS) is a multi-symptomatic genetic disorder associated with abnormalities in the growth hormone (GH)-insulin-like-growth factor (IGF)-I axis and in the body composition. GH treatment is a registered indication in children with PWS, and improves growth rate and body composition. One pilot study in adult patients with clinical PWS has shown beneficial effects on body composition without simultaneous significant side effects. The aim of the present study is to evaluate the effects of GH treatment on body composition, muscle function and quality of life in PWS adults.
TRIAL DESIGN:
The study will be an investigator initiated and investigator sponsored multinational and multi-centre trial, including centres in Norway, Sweden and Denmark. Within each centre patients will be randomised (double blind) to one year treatment with daily injections of GH or placebo (efficacy), followed by a two year observation period on GH treatment (safety).
TRIAL POPULATION:
Twenty patients from each centre are included in the study. The patients need a genetically verified diagnosis and should be between 18 and 40 years old. Patients are excluded if GH treatment has been given within the last two years, if they have a malignancy or other serious diseases, in particular severe respiratory diseases.
ASSESSMENTS:
Effect is evaluated primarily as changes in body composition, activity of daily living and quality of life.
SAFETY: Before starting in the study all patients will be examined for tonsillary hypertrophy and sleep apnoea. Oral Glucose Tolerance Tests will be performed regularly.
TRIAL PRODUCT(S):
During the initial 4 weeks of the placebo-controlled study phase patients will be treated with sc injections of GH (Norditropin Simplexx) in the evening with doses of 0.3 mg/day respectively 0.4 mg/day if BW is below or above 100 kg. Thereafter doses will be increased to 0.6 mg/day (0.8 mg/day) and maintained fixed for 11 months. During the following 24 months open phase doses will be individually titrated.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 46
- Genetically verified PWS diagnosis (by methylation and FISH test.)
- Between 18 and 50 years old
- Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the treatment of the subject.)
- Known or suspected allergy to GH preparation.
- Previous participation in this trial.
- GH treatment within the last 1 years
- Malignancy or other serious diseases (ex severe cardiovascular diseases, severe infections)
- Sexhormone treatment initiated within the last year
- Pregnancy
- Untreated respiratory impairment, untreated sleep apnoea or untreated respiratory infection.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Norditropin SimpleXx Norditropin SimpleXx 0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months. Placebo Norditropin SimpleXx Placebo for 12 months
- Primary Outcome Measures
Name Time Method Changes in body composition (lean body mass and fat mass) measured by dual energy X-ray absorptiometry (DXA) 36 months
- Secondary Outcome Measures
Name Time Method Standard photography appearance according to visual analogue scale (VAS) 36 months Effects on free and total IGF-I, IGF-binding protein (BP)-1 and 3 36 months Effects on lipids (fasting triglycerides(TG), total, HDL and LDL cholesterol) 36 months Effects on body composition measured with bioimpedance 36 months Bone mineral density measured by DXA 36 months Effects on forced expiratory volume (Peakflow) 36 months Activity of daily living measured a.m. Guralnik 36 months Effects on haemoglobin (Hb), leucocyte and thrombocyte counts, FSH, LH, estradiol, Testosterone, inhibin B, TSH and Thyroxine 36 months Muscle and fat mass measured by abdominal and mid-femoral computerized tomography 36 months Quality of life estimated by questionnaires 36 months
Trial Locations
- Locations (3)
Department of Endocrinology and Diabetology, Karolinska Hospital
🇸🇪Stockholm, Sweden
Center for rare Diseases, Department of Pediatrics, Skejby University Hospital
🇩🇰Aarhus N, Denmark
Endokrinologisk seksjon, Med Avd, Rikshospitalet
🇳🇴Oslo, Norway